Literature DB >> 19856393

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors.

Catherine Lam1, Eric Bouffet, Uri Tabori, Donald Mabbott, Michael Taylor, Ute Bartels.   

Abstract

Tuberous sclerosis complex (TSC) is associated with hamartomatous growths including subependymal giant cell astrocytomas (SEGAs). Since chemo-radiation therapies offer scant benefit, oncologists had traditionally been little involved in managing SEGAs. Recent evidence demonstrating rapamycin efficacy in adults and children with TSC-associated tumors foresee a practice change. We summarize our institutional experience and literature review that highlight potential benefits and hazards of rapamycin therapy, for TSC patients with SEGA, and other syndromal brain tumors. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19856393     DOI: 10.1002/pbc.22298

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  24 in total

Review 1.  Deconvoluting mTOR biology.

Authors:  Jason D Weber; David H Gutmann
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 2.  Targeted therapy in pediatric low-grade glioma.

Authors:  John-Paul Kilday; Ute Katharina Bartels; Eric Bouffet
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

3.  The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis.

Authors:  Tao Jiang; Ge Jia; ZhenYu Ma; ShiQi Luo; YuQi Zhang
Journal:  Childs Nerv Syst       Date:  2010-04-27       Impact factor: 1.475

Review 4.  Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes.

Authors:  Maya B Lodish; Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

5.  Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.

Authors:  A M Cappellano; A A Senerchia; F Adolfo; P M Paiva; R Pinho; A Covic; S Cavalheiro; N Saba
Journal:  Childs Nerv Syst       Date:  2013-06-07       Impact factor: 1.475

6.  Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex.

Authors:  Michal Yalon; L Ben-Sira; S Constantini; A Toren
Journal:  Childs Nerv Syst       Date:  2010-08-12       Impact factor: 1.475

Review 7.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

8.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

Review 9.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

Review 10.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.